Astrana Health, Inc. announced it has successfully closed the acquisition of Prospect Health for a revised total purchase price of $708 million, down from the originally announced $745 million. The acquisition aims to enhance Astrana's capabilities in delivering high-quality and high-value care across the nation. The company expects Prospect Health to contribute approximately $1.2 billion in total revenue and $81 million in adjusted EBITDA annually. Astrana has updated its full-year 2025 guidance, projecting total revenue between $3.1 billion and $3.3 billion and adjusted EBITDA between $215 million and $225 million. The acquisition is expected to generate $12 million to $15 million in synergies over the next twelve to eighteen months. With this transaction, Astrana's net debt stands at $700 million, and the company is committed to reducing its net leverage ratio below 2.5x in the coming months.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.